Syndax Pharmaceuticals Inc. has appointed Dr. Nicholas Botwood as the new Head of Research and Development and Chief Medical Officer. Dr. Botwood, previously with Bristol Myers Squibb, brings over 25 years of experience in drug development and oncology. He succeeds Dr. Neil Gallagher, who is leaving the company.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Syndax Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000950170-25-073555), on May 16, 2025, and is solely responsible for the information contained therein.